Open Access 22-04-2025 | Breast Cancer | Review

Therapy of early breast cancer: current status and perspectives

Authors: Nikolas Tauber, Niklas Amann, Dominik Dannehl, Thomas M. Deutsch, Moritz Dimpfl, Peter Fasching, Andreas Hartkopf, Sabine Heublein, Lisbeth Hilmer, Manuel Hörner, Natalia Krawczyk, Annika Krückel, David Krug, Frederik Marmé, Laura L. Michel, Mattea Reinisch, Achim Rody, Henning Schäffler, Andreas Schneeweiss, David Utz, Kristina Veselinovic, Maggie Banys-Paluchowski

Published in: Archives of Gynecology and Obstetrics

Abstract

Medical advancements in breast cancer are truly remarkable. Especially in recent years, numerous new therapeutics have been approved and surgical strategies have been de-escalated for specific patient groups. In the therapeutic setting, CDK4/6 inhibitors as oral maintenance therapy in early breast cancer and immune checkpoint inhibitors (Pembrolizumab) for triple-negative breast cancer (BC) are noteworthy. In the surgical field, prospective randomized controlled trials have currently explored the possibility to deescalate axillary surgery by omitting sentinel lymph node excision (INSEMA, SOUND). As a result, there have been significant improvements in prognosis and a reduction in surgical morbidity for patients. Many exciting trials are underway, and it remains to be seen whether antibody–drug conjugates beyond trastuzumab emtansine, will find their way into the treatment lines for early-stage BC. Furthermore, the integration of artificial intelligence in both diagnostics and treatment recommendation evaluation is a promising area with great potential.

Park-Simon TW, Müller V, Albert US, Banys Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer JU, Budach W, Dall P et al (2025) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2025. Breast Care. https://doi.org/10.1159/000545019CrossRefPubMedPubMedCentral

Zentrum für Krebsregisterdaten, R.K.I. Brustkrebs (Mammakarzinom). Available online: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html. Accessed on 02 Jan 2025.

Wallwiener M, Brucker SY, Wallwiener D (2012) Multidisciplinary breast centres in Germany: a review and update of quality assurance through benchmarking and certification. Arch Gynecol Obstet 285:1671–1683. https://doi.org/10.1007/s00404-011-2212-3CrossRefPubMedPubMedCentral

Schoffer O, Wimberger P, Gerken M, Bierbaum V, Bobeth C, Rößler M, Dröge P, Ruhnke T, Günster C, Kleihues-van Tol K et al (2024) Treatment in certified breast cancer centers improves chances of survival of patients with breast cancer. Evid Based Health Care Data WiZen Study 84:153–163. https://doi.org/10.1055/a-1869-1772CrossRef

Eisemann N, Bunk S, Mukama T, Baltus H, Elsner SA, Gomille T, Hecht G, Heywang-Köbrunner S, Rathmann R, Siegmann-Luz K et al (2025) Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nat Med. https://doi.org/10.1038/s41591-024-03408-6CrossRefPubMedPubMedCentral

AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2025. Available online: https://www.ago-online.de/ago-kommissionen/kommission-mamma. Accessed on 08 Mar 2025.

Kaufmann M, von Minckwitz G, Bergh J, Conte PF, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D, Senn HJ et al (2013) Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Arch Gynecol Obstet 288:1203–1212. https://doi.org/10.1007/s00404-013-3069-4CrossRefPubMed

de Boniface J, Szulkin R, Johansson AL (2021) Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg 156:628–637CrossRefPubMedPubMedCentral

Christiansen P, Carstensen SL, Ejlertsen B, Kroman N, Offersen B, Bodilsen A, Jensen M-B (2018) Breast conserving surgery versus mastectomy: overall and relative survival—a population based study by the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol 57:19–25CrossRefPubMed

10.

Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V et al (2022) AGO recommendations for the surgical therapy of breast cancer: update 2022. Geburtshilfe Frauenheilkd 82:1031–1043. https://doi.org/10.1055/a-1904-6231CrossRefPubMedPubMedCentral

11.

Banys-Paluchowski M, Rubio IT, Cakmak GK, Esgueva A, Krawczyk N, Paluchowski P, Gruber I, Marx M, Brucker SY, Bündgen N (2022) Intraoperative ultrasound-guided excision of non-palpable and palpable breast cancer: systematic review and meta-analysis. Ultraschall in der Medizin-Eur J Ultrasound 43:367–379CrossRef

12.

Pantiora E, Jazrawi A, Hersi AF, Abdsaleh S, Ahlstedt H, Molnar E, Wärnberg F, Eriksson S, Karakatsanis A (2024) Magnetic seed vs guidewire breast cancer localization with magnetic lymph node detection: a randomized clinical trial. JAMA Surg 159:239–246. https://doi.org/10.1001/jamasurg.2023.6520CrossRefPubMed

13.

Banys-Paluchowski M, Kühn T, Masannat Y, Rubio I, de Boniface J, Ditsch N, Karadeniz Cakmak G, Karakatsanis A, Dave R, Hahn M et al (2023) Localization techniques for non-palpable breast lesions: current status, knowledge gaps, and rationale for the MELODY study (EUBREAST-4/iBRA-NET, NCT 05559411). Cancers (Basel). https://doi.org/10.3390/cancers15041173CrossRefPubMedPubMedCentral

14.

Marinovich ML, Azizi L, Macaskill P, Irwig L, Morrow M, Solin LJ, Houssami N (2016) The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 23:3811–3821CrossRefPubMedPubMedCentral

15.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol 34:4040–4046CrossRefPubMedPubMedCentral

16.

Schnitt SJ, Moran MS, Giuliano AE (2020) Lumpectomy margins for invasive breast cancer and ductal carcinoma in situ: current guideline recommendations, their implications, and impact. J Clin Oncol 38:2240–2245CrossRefPubMed

17.

Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ et al (2023) Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). J Clin Oncol 41:3184–3193. https://doi.org/10.1200/JCO.22.02553CrossRefPubMedPubMedCentral

18.

Lambertini, M., et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study. In Proceedings of the San Antonio Breast Cancer Symposium, 2024.

19.

Sessa C, Balmaña J, Bober S, Cardoso M-J, Colombo N, Curigliano G, Domchek S, Evans D, Fischerova D, Harbeck N (2023) Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline☆. Ann Oncol 34:33–47CrossRefPubMed

20.

Mallon P, Feron J-G, Couturaud B, Fitoussi A, Lemasurier P, Guihard T, Cothier-Savay I, Reyal F (2013) The role of nipple-sparing mastectomy in breast cancer: a comprehensive review of the literature. Plast Reconstr Surg 131:969–984CrossRefPubMed

21.

Badwe RA, Parmar V, Nair N, Joshi S, Hawaldar R, Pawar S, Kadayaprath G, Borthakur BB, Rao Thammineedi S, Pandya S et al (2023) Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer. J Clin Oncol 41:3318–3328. https://doi.org/10.1200/JCO.22.01966CrossRefPubMed

22.

Tauber N, Bjelic-Radisic V, Thill M, Banys-Paluchowski M (2024) Controversies in axillary management of patients with breast cancer - updates for 2024. Curr Opin Obstet Gynecol 36:51–56. https://doi.org/10.1097/gco.0000000000000916CrossRefPubMed

23.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical Trial. JAMA 318:918–926. https://doi.org/10.1001/jama.2017.11470CrossRefPubMedPubMedCentral

24.

de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M et al (2024) Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med 390:1163–1175. https://doi.org/10.1056/NEJMoa2313487CrossRefPubMed

25.

Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V et al (2024) Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol 10:793–798. https://doi.org/10.1001/jamaoncol.2024.0578CrossRefPubMed

26.

Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072–1078. https://doi.org/10.1200/jco.2015.64.0094CrossRefPubMedPubMedCentral

27.

Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio A, Morrow M (2018) Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol 25:1488–1494. https://doi.org/10.1245/s10434-018-6429-2CrossRefPubMedPubMedCentral

28.

Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV et al (2024) Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05/ICARO study. J Clin Oncol. https://doi.org/10.1200/jco.24.01052CrossRefPubMed

29.

Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, Luini A, Viale G, Cassano E, Peradze N et al (2023) Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol 9:1557–1564. https://doi.org/10.1001/jamaoncol.2023.3759CrossRefPubMedPubMedCentral

30.

Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marmé F, Müller T, Hildebrandt G, Krug D et al (2024) Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med. https://doi.org/10.1056/NEJMoa2412063CrossRefPubMed

31.

Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, Barrett-Lee P, Bliss P, Bloomfield D, Bowen J et al (2020) Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 38:3261–3272. https://doi.org/10.1200/jco.19.02750CrossRefPubMedPubMedCentral

32.

Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395:1613–1626. https://doi.org/10.1016/s0140-6736(20)30932-6CrossRefPubMedPubMedCentral

33.

Krug D, Baumann R, Combs SE, Duma MN, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T et al (2021) Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward. Strahlenther Onkol 197:269–280. https://doi.org/10.1007/s00066-020-01744-3CrossRefPubMedPubMedCentral

34.

Jagsi R, Griffith KA, Harris EE, Wright JL, Recht A, Taghian AG, Lee L, Moran MS, Small W Jr, Johnstone C et al (2024) Omission of radiotherapy after breast-conserving surgery for women with breast cancer with low clinical and genomic risk: 5-year outcomes of IDEA. J Clin Oncol 42:390–398. https://doi.org/10.1200/jco.23.02270CrossRefPubMed

35.

Whelan TJ, Smith S, Parpia S, Fyles AW, Bane A, Liu FF, Rakovitch E, Chang L, Stevens C, Bowen J et al (2023) Omitting radiotherapy after breast-conserving surgery in luminal a breast cancer. N Engl J Med 389:612–619. https://doi.org/10.1056/NEJMoa2302344CrossRefPubMed

36.

Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD et al (2018) Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review. Strahlenther Onkol 194:607–618. https://doi.org/10.1007/s00066-018-1270-xCrossRefPubMed

37.

Zhao X, Huang S, Lin H, Choi JI, Zhu K, Simone CB, Yan X, Kang M (2024) A novel dose rate optimization method to maximize ultrahigh-dose-rate coverage of critical organs at risk without compromising dosimetry metrics in proton pencil beam scanning FLASH radiation therapy. Int J Radiat Oncol Biol Phys 120:1181–1191. https://doi.org/10.1016/j.ijrobp.2024.06.002CrossRefPubMed

38.

Wong JS, Uno H, Tramontano AC, Fisher L, Pellegrini CV, Abel GA, Burstein HJ, Chun YS, King TA, Schrag D et al (2024) Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical Trial. JAMA Oncol 10:1370–1378. https://doi.org/10.1001/jamaoncol.2024.2652CrossRefPubMed

39.

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310. https://doi.org/10.1016/s1470-2045(14)70460-7CrossRefPubMedPubMedCentral

40.

Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M et al (2024) Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. Radiother Oncol 197:110372. https://doi.org/10.1016/j.radonc.2024.110372CrossRefPubMed

41.

Algara M, Rodríguez E, Martínez-Arcelus FJ, Salinas J, Sanz X, Beato I, Manso A, Soler A, Rodríguez JR, Frías A et al (2022) OPTimizing irradiation through molecular assessment of lymph node (OPTIMAL): a randomized clinical trial. Radiother Oncol 176:76–82. https://doi.org/10.1016/j.radonc.2022.09.006CrossRefPubMed

42.

Radiotherapy to regional nodes in early breast cancer (2023) an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet 402:1991–2003. https://doi.org/10.1016/s0140-6736(23)01082-6CrossRef

43.

Mamounas E, Bandos H, White J, Julian T, Khan A, Shaitelman S, Torres M, Vicini F, Ganz P, McCloskey S et al (2024) Abstract GS02–07: loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG oncology/NSABP B-51/RTOG 1304. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS23-GS02-07CrossRef

44.

Meattini I, Coles CE, Tramm T, Borghesi S, Krug D, Montero A, Nardone V, Salvestrini V, Valzano M, Valentini V et al (2025) Biomarker-directed radiotherapy in breast cancer: a narrative review. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2024.5780CrossRefPubMed

45.

Hartmann S, Kühn T, Hauptmann M, Stickeler E, Thill M, Lux MP, Fröhlich S, Ruf F, Loibl S, Blohmer J-U et al (2022) Axillary staging after neoadjuvant chemotherapy for initially node-positive breast carcinoma in Germany. Initial Data AXSANA Study 82:932–940. https://doi.org/10.1055/a-1889-7883CrossRef

46.

Mailhot Vega R, Deladisma AM, Mobley EM, Wang S, Morris CG, Oladeru OT, Brooks E, Gharia BM, Spiguel LR, MacDonald SM et al (2023) Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41. J Clin Oncol 41:524–524. https://doi.org/10.1200/JCO.2023.41.16_suppl.524CrossRef

47.

Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol: Off J Am Soc Clin Oncol 41:3867–3872. https://doi.org/10.1200/JCO.22.02864CrossRef

48.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182. https://doi.org/10.1126/science.3798106CrossRefPubMed

49.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283. https://doi.org/10.1056/NEJMoa0910383CrossRefPubMedPubMedCentral

50.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. https://doi.org/10.1056/NEJMoa052122CrossRefPubMed

51.

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ et al (2024) Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:331–357. https://doi.org/10.6004/jnccn.2024.0035CrossRefPubMed

52.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131. https://doi.org/10.1056/NEJMoa1703643CrossRef

53.

Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH et al (2025) Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med 392:249–257. https://doi.org/10.1056/NEJMoa2406070CrossRefPubMed

54.

Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK et al (2023) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 24:273–285. https://doi.org/10.1016/s1470-2045(23)00051-7CrossRefPubMed

55.

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B (2023) Understanding breast cancer complexity to improve patient outcomes: The St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 34:970–986. https://doi.org/10.1016/j.annonc.2023.08.017CrossRefPubMed

56.

Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH et al (2021) Final efficacy results of neratinib in her2-positive hormone receptor-positive early-stage breast cancer from the Phase III ExteNET Trial. Clin Breast Cancer 21:80–91. https://doi.org/10.1016/j.clbc.2020.09.014CrossRefPubMed

57.

Tauber N, Cirkel C, Claussen A, Fick F, Kontomanolis E, Krawczyk N, Rody A, Banys-Paluchowski M (2024) HER2-positive early breast cancer: time for ultimate de-escalation? Cancers (Basel). https://doi.org/10.3390/cancers16061121CrossRefPubMed

58.

Perez-Garcia JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marme F, Escriva-de-Romani S, Calvo L, Ribelles N et al (2021) Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 22:858–871. https://doi.org/10.1016/S1470-2045(21)00122-4CrossRefPubMed

59.

Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke EM, Augustin D, Braun M et al (2023) Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial. Clin Cancer Res : Off J Am Assoc Cancer Res 29:805–814. https://doi.org/10.1158/1078-0432.CCR-22-1587CrossRef

60.

Malorni L et al: 2024 SABCS; RF1–02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ EBC: primary results from the randomized phase II TOUCH trial (IBCSG 55–17).

61.

Harbeck N et al (2021) SABCS; OT1–12–04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early breast cancer (DESTINY-Breast11). Cancer Res. https://doi.org/10.1158/1538-7445.SABCS21-OT1-12-04CrossRef

62.

Geyer C, Untch M, Prat A, Rastogi P, Niikura N, Mathias E, McLean L, Wang Y, Loibl S (2022) Abstract OT1–02–03: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Res. https://doi.org/10.1158/1538-7445.SABCS21-OT1-02-03CrossRef

63.

Harbeck N, Braun M, Gluz O, Schmid P, Graeser MK, Hartkopf AD, Hoffmann O, Kostara A, Polata S, Volmer LL et al (2024) Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel plus carboplatin plus trastuzumab plus pertuzumab in HER2+early breast cancer: WSG-ADAPT-HER2-IV. J Clin Oncol. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS631CrossRefPubMedPubMedCentral

64.

McArthur HL et al: 2024 SABCS; RF3–05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP).

65.

Niravath P et al: 2024 SABCS; RF1–07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.

66.

Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G (2022) Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 8:23. https://doi.org/10.1038/s41523-022-00386-1CrossRefPubMedPubMedCentral

67.

Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L et al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159–182. https://doi.org/10.1016/j.annonc.2023.11.016CrossRefPubMed

68.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39. https://doi.org/10.1016/s1470-2045(17)30777-5CrossRef

69.

Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A (2023) Platinum-based chemotherapy for early triple-negative breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD014805.pub2CrossRefPubMedPubMedCentral

70.

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981–1991. https://doi.org/10.1056/NEJMoa2409932CrossRefPubMed

71.

Tolaney S, Ballman K, Perou CM, Cescon D, Gatti-Mays M, Blinder V, Rosenberg S, Mittendorf E, Weiss A, Rugo H et al (2024) Abstract PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103). Cancer Res. https://doi.org/10.1158/1538-7445.SABCS23-PO4-19-05CrossRef

72.

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304–311. https://doi.org/10.1200/jco.2014.57.1414CrossRefPubMed

73.

Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384:440–451. https://doi.org/10.1056/NEJMoa2005936CrossRefPubMedPubMedCentral

74.

Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K (2022) Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol 14:17588359221096252. https://doi.org/10.1177/17588359221096253CrossRefPubMedPubMedCentral

75.

Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 33:1250–1268. https://doi.org/10.1016/j.annonc.2022.09.159CrossRefPubMed

76.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159. https://doi.org/10.1056/NEJMoa1612645CrossRefPubMed

77.

Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P (2020) Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US From 2010 to 2016. JAMA Netw Open 3:e2013226. https://doi.org/10.1001/jamanetworkopen.2020.13226CrossRefPubMedPubMedCentral

78.

Institute, N.C. Female Breast Cancer- Cancer Stat Fact. Available online: https://seer.cancer.gov/statfacts/html/breast.html. Accessed on 15 Jan 2025.

79.

Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C et al (2024) Analysis of breast cancer mortality in the US-1975 to 2019. JAMA 331:233–241. https://doi.org/10.1001/jama.2023.25881CrossRefPubMedPubMedCentral

80.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2024) Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet, 404: 1407–1418, https://doi.org/10.1016/s0140-6736(24)01745-8.

81.

Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, Campadelli E, Cognetti F, Frassoldati A, Michelotti A et al (2021) Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:1458–1467. https://doi.org/10.1016/s1470-2045(21)00352-1CrossRefPubMed

82.

Jhaveri K, Pegram M, Neven P, Curigliano G, Spring LM, Gligorov J, Schlam I, Harbeck N, Juric D, Lim E et al (2024) 292P Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR). Ann Oncol 35:S337–S338. https://doi.org/10.1016/j.annonc.2024.08.233CrossRef

83.

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM et al (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update. J Clin Oncol 40:1816–1837. https://doi.org/10.1200/jco.22.00069CrossRefPubMed

84.

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thurlimann B et al (2023) Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 34:970–986. https://doi.org/10.1016/j.annonc.2023.08.017CrossRefPubMed

85.

Fasching PA, Kreipe H, Del Mastro L, Ciruelos E, Freyer G, Korfel A, Chouaki N, Stoffregen C, Sapunar F, Cameron D (2024) Identification of patients with early HR+ HER2− breast cancer at high risk of recurrence. Geburtshilfe Frauenheilkd 84:164–184. https://doi.org/10.1055/a-2238-3199CrossRefPubMedPubMedCentral

86.

Kolberg H-C, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C et al (2023) Update breast cancer 2023 part 3–expert opinions of early stage breast cancer therapies. Geburtshilfe Frauenheilkd 83:1117–1126. https://doi.org/10.1055/a-2143-8125CrossRefPubMedPubMedCentral

87.

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, anderson B, burstein hj, chew h et al (2023) NCCN guidelines® insights: breast cancer version.4.2023. J Natl Compr Canc Netw 21:594–608. https://doi.org/10.6004/jnccn.2023.0031CrossRefPubMed

88.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121. https://doi.org/10.1056/NEJMoa1804710CrossRefPubMedPubMedCentral

89.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL et al (2021) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385:2336–2347. https://doi.org/10.1056/NEJMoa2108873CrossRefPubMedPubMedCentral

90.

Cardoso F, van Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M et al (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729. https://doi.org/10.1056/NEJMoa1602253CrossRefPubMed

91.

Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA et al (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw050CrossRefPubMedPubMedCentral

92.

Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C et al (2022) endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+/HER2- early breast cancer. J Clin Oncol 40:2557–2567. https://doi.org/10.1200/jco.21.02759CrossRefPubMed

93.

Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M et al (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 21:1443–1454. https://doi.org/10.1016/s1470-2045(20)30458-7CrossRefPubMedPubMedCentral

94.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 393, 1440–1452, https://doi.org/10.1016/s0140-6736(18)33137-4.

95.

Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA et al (2021) A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer 7:134. https://doi.org/10.1038/s41523-021-00342-5CrossRefPubMedPubMedCentral

96.

de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, Fehm T, Kreipe H, Christgen M et al (2022) The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer 126:1715–1724. https://doi.org/10.1038/s41416-021-01690-6CrossRefPubMedPubMedCentral

97.

Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F et al (2019) West German study planb trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 37:799–808. https://doi.org/10.1200/jco.18.00028CrossRefPubMed

98.

Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC et al (2023) Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer a systematic review and meta-analysis of randomized clinical trials. Breast 69:258–264. https://doi.org/10.1016/j.breast.2023.02.012CrossRefPubMedPubMedCentral

99.

Gray RG, Bradley R, Braybrooke J, Clarke M, Hills RK, Peto R, Bergh JCS, Swain SM, Davidson NE, Francis PA et al (2023) Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. J Clin Oncol 41:503–503. https://doi.org/10.1200/JCO.2023.41.16_suppl.503CrossRef

100.

Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C et al (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 23:382–392. https://doi.org/10.1016/S1470-2045(21)00758-0CrossRef

101.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816. https://doi.org/10.1016/s0140-6736(12)61963-1CrossRefPubMedPubMedCentral

102.

Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. https://doi.org/10.1200/jco.2013.31.18_suppl.5CrossRefPubMedPubMedCentral

103.

Choong GMY, Hoskin TL, Boughey JC, Ingle JN, Goetz MP (2024) The impact of adjuvant endocrine therapy (AET) omission in ER-low (1–10%) early-stage breast cancer. J Clin Oncol 42:513–513. https://doi.org/10.1200/JCO.2024.42.16_suppl.513CrossRef

104.

Adams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M, Caro-Valenzuela J, Wöckel A, Skoetz N (2024) Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013451.pub2CrossRefPubMedPubMedCentral

105.

Rastogi P, O’Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E et al (2024) Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 42:987–993. https://doi.org/10.1200/jco.23.01994CrossRefPubMedPubMedCentral

106.

Fasching PA, Stroyakovskiy D, Yardley D, Huang CS, Crown JP, Bardia A, Chia S, Im SA, Martin Jimenez M, Xu B et al (2024) LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol. https://doi.org/10.1016/j.annonc.2024.08.2251CrossRefPubMed

107.

Schäffler H, Mergel F, Pfister K, Lukac S, Fink A, Veselinovic K, Rack B, Fink V, Leinert E, Dimpfl M et al (2023) The clinical relevance of the NATALEE study: application of the NATALEE Criteria to a real-world cohort from two large german breast cancer centers. Int J Mol Sci. https://doi.org/10.3390/ijms242216366CrossRefPubMedPubMedCentral

108.

Dannehl D, Volmer LL, Weiss M, Matovina S, Grischke EM, Oberlechner E, Seller A, Walter CB, Hahn M, Engler T et al (2022) Feasibility of adjuvant treatment with abemaciclib-real-world data from a large german breast center. J Pers Med. https://doi.org/10.3390/jpm12030382CrossRefPubMedPubMedCentral

109.

Dannehl D, Engler T, Volmer LL, Tegeler CM, Fusshoeller J, Gabrysch E, Eissler K, Seller A, Grischke E-M, Hahn M et al (2023) Which patients do we need to test for BRCA1/2 mutation? Feasibility of adjuvant olaparib treatment in early breast cancer–real-world data from two large german breast centers. Cancers. https://doi.org/10.3390/cancers15153847CrossRefPubMedPubMedCentral

110.

Tauber N, Hilmer L, Dannehl D, Fick F, Hemptenmacher F, Krawczyk N, Meyer-Lehnert T, Milewski K, Princk H, Hartkopf A et al (2025) Oral maintenance therapy in early breast cancer—how many patients are potential candidates? Cancers. https://doi.org/10.3390/cancers17010145CrossRefPubMedPubMedCentral

111.

Frevert ML, Dannehl D, Jansen L, Hermann S, Schäffler H, Huwer S, Janni W, Juhasz-Böss I, Hartkopf AD, Taran FA (2024) Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry. Arch Gynecol Obstet 309:2811–2819. https://doi.org/10.1007/s00404-024-07405-5CrossRefPubMedPubMedCentral

112.

Geyer C, Bardia A, Harbeck N, Rimawi MF, Hurvitz SA, Martin M, Loi S, Saji S, Jung KH, Werutsky G et al (2023) lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive HER2-negative early BC (ER+, HER2– eBC). J Clin Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS616CrossRefPubMedPubMedCentral

113.

Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA et al (2025) Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial. Nat Med. https://doi.org/10.1038/s41591-024-03415-7CrossRefPubMedPubMedCentral

114.

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H et al (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6:676–684. https://doi.org/10.1001/jamaoncol.2019.6650CrossRefPubMed

115.

Loi S, Curigliano G, Salgado RF, Romero Diaz RI, Delaloge S, Rojas C, Kok M, Saura Manich C, Harbeck N, Mittendorf EA et al (2023) LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) & #xb1; NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). Ann Oncol 34:S1259–S1260. https://doi.org/10.1016/j.annonc.2023.10.010CrossRef

116.

Pfister K, Huesmann S, Friedl TWP, Fink A, Mehmeti F, Mergel F, Schäffler H, Heublein S, Hartkopf AD, Mueller V et al (2024) The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS620CrossRefPubMedPubMedCentral

117.

Pfister K, Friedl TWP, Huesmann ST, Mergel F, Fink A, Mehmeti F, Uhl N, Schäffler H, Lukac S, Koretz K et al (2024) The SURVIVE HERoes trial – a secondary adjuvant treatment intervention study with trastuzumab deruxtecan (Enhertu) in early breast cancer patients with HER2-positive/HER2-low tumors and molecular relapse. GebFra 84:198–199. https://doi.org/10.1055/s-0044-1790908CrossRef

118.

Lukac S, Dayan D, Fink V, Leinert E, Hartkopf A, Veselinovic K, Janni W, Rack B, Pfister K, Heitmeir B et al (2023) Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases. Arch Gynecol Obstet 308:1831–1844. https://doi.org/10.1007/s00404-023-07130-5CrossRefPubMedPubMedCentral

119.

Griewing S, Gremke N, Wagner U, Wallwiener M, Kuhn S, Commission Digital Medicine of the German Society for, G.; Obstetrics (2024) Current developments from silicon valley–how artificial intelligence is changing gynecology and obstetrics. Geburtshilfe Frauenheilkd 84:1118–1125. https://doi.org/10.1055/a-2335-6122CrossRefPubMedPubMedCentral

Title: Therapy of early breast cancer: current status and perspectives
Authors: Nikolas Tauber
Niklas Amann
Dominik Dannehl
Thomas M. Deutsch
Moritz Dimpfl
Peter Fasching
Andreas Hartkopf
Sabine Heublein
Lisbeth Hilmer
Manuel Hörner
Natalia Krawczyk
Annika Krückel
David Krug
Frederik Marmé
Laura L. Michel
Mattea Reinisch
Achim Rody
Henning Schäffler
Andreas Schneeweiss
David Utz
Kristina Veselinovic
Maggie Banys-Paluchowski
Publication date: 22-04-2025
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Mastectomy
Radiotherapy
Endocrine Therapy
Published in: Archives of Gynecology and Obstetrics
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-025-08028-0

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Therapy of early breast cancer: current status and perspectives

Abstract

Women’s health knowledge hub

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Women’s health knowledge hub

Keynote series | Spotlight on menopause